| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.33 | 1e-21 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.29 | 3e-19 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-12 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-12 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-11 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.3 | 5e-10 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 8e-10 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.17 | 8e-09 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-08 |